Topics:

Sanofi CEO uses Lemtrada's step forward to tout R&D future

Tools
Sanofi CEO Chris Viehbacher

Sanofi ($SNY) CEO Chris Viehbacher paid tribute to his Genzyme unit's MS drug candidate Lemtrada as the FDA accepted the company's application for its U.S. approval. Viehbacher also pointed to Sanofi's retooled R&D operation--and outlined plans for bolt-on deals, provided he can find some decently priced assets. Report

 

Filed Under